Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells

被引:30
|
作者
Fabbri, F
Brigliadori, G
Ulivi, P
Tesei, A
Vannini, I
Rosetti, M
Bravaccini, S
Amadori, D
Bolla, M
Zoli, W
机构
[1] Morgagni Pierantoni Hosp, Div Oncol & Diagnost, I-47100 Forli, Italy
[2] Morgagni Pierantoni Hosp, Ist Oncol Romagnolo, I-47100 Forli, Italy
[3] NicOx SA, Sophia Antipolis, France
关键词
apoptosis; bladder cancer; NO-NSAID;
D O I
10.1007/s10495-005-0619-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nitric oxide-releasing non steroidal anti-inflammatory drugs (NO-NSAIDs) are a promising class of compounds that cause cell cycle perturbations and induce apoptosis in cell lines from different tumors. We investigated the activity of a recently developed NO-NSAID (NCX 4040) in bladder cancer cell lines (HT1376 and MCR). Cells were treated with different drug concentrations for different exposure times. Cytostatic and cytocidal activity was tested by SRB assay and apoptosis was evaluated by TUNEL analysis, ANNEXIN V assay and fluorescence microscopy. To further investigate the cell death-inducing mechanisms of NCX 4040, we analyzed gp-170, caspase expression and mitochondrial membrane potential (Delta psi) depolarization. NCX 4040 showed a striking cytocidal activity in both cell lines, reaching LC50 at a 10-mu M and 50-mu M concentrations in HT1376 and in MCR cells, respectively, after an exposure of only 6 h followed by an 18-h washout. Apoptosis was triggered in up to 90% of cells and was associated with active caspase-3 expression and Delta psi depolarization in both cell lines after a 6-h exposure. In conclusion, NCX 4040, which probably causes apoptosis via a mitochondrial-dependent mechanism, could prove to be a useful agent for improving bladder cancer treatment.
引用
收藏
页码:1095 / 1103
页数:9
相关论文
共 50 条
  • [1] Pro-apoptotic effect of a nitric oxide-donating NSAID, NCX 4040, on bladder carcinoma cells
    F. Fabbri
    G. Brigliadori
    P. Ulivi
    A. Tesei
    I. Vannini
    M. Rosetti
    S. Bravaccini
    D. Amadori
    M. Bolla
    W. Zoli
    Apoptosis, 2005, 10 : 1095 - 1103
  • [2] The effect of NCX 4016 and NCX 4040, two nitric oxide-donating aspirin derivatives, on apoptosis of neutrophil granulocytes in vitro
    Vasilev, S.
    Majstorovic, I.
    Vucevic, D.
    Gasic, S.
    Vasilijic, S.
    Bufan, B.
    Cupic, V.
    Colic, M.
    TOXICOLOGY LETTERS, 2005, 158 : S229 - S229
  • [3] The effect of NCX1102, a nitric oxide-donating derivative of sulindac, on prostate cancer cells under hypoxia
    Stewart, G. D.
    Nanda, J.
    Brown, D. J. G.
    Riddick, A. C. P.
    Ross, J. A.
    Habib, F. K.
    BJU INTERNATIONAL, 2007, 99 : 47 - 47
  • [4] Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines
    Tesei, Anna
    Rosetti, Marco
    Ulivi, Paola
    Fabbri, Francesco
    Medri, Laura
    Vannini, Ivan
    Bolla, Manlio
    Amadori, Dino
    Zoli, Wainer
    JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
  • [5] Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines
    Anna Tesei
    Marco Rosetti
    Paola Ulivi
    Francesco Fabbri
    Laura Medri
    Ivan Vannini
    Manlio Bolla
    Dino Amadori
    Wainer Zoli
    Journal of Translational Medicine, 5
  • [6] NCX 4040, a nitric oxide-donating aspirin derivative, inhibits Prevotella intermedia lipopolysaccharide-induced production of proinflammatory mediators in murine macrophages
    Choi, Eun-Young
    Choe, So-Hui
    Hyeon, Jin-Yi
    Park, Hae Ryoun
    Choi, Jeom-Il
    Choi, In Soon
    Kim, Sung-Jo
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 768 : 87 - 95
  • [7] NCX4040, a nitric oxide (NO) donating form of aspirin as a potential treatment for prostate cancer
    Chinnapaka, Somaiah
    Munirathinam, Gnanasekar
    CANCER RESEARCH, 2019, 79 (13)
  • [8] NCX 4040, a Nitric Oxide-Donating Aspirin, Exerts Anti-Inflammatory Effects through Inhibition of IκB-α Degradation in Human Monocytes
    Ricciotti, Emanuela
    Dovizio, Melania
    Di Francesco, Luigia
    Anzellotti, Paola
    Salvatore, Tania
    Di Francesco, Andrea
    Sciulli, Maria G.
    Pistritto, Giuseppa
    Monopoli, Angela
    Patrignani, Paola
    JOURNAL OF IMMUNOLOGY, 2010, 184 (04): : 2140 - 2147
  • [9] Antiproliferative effect of nitrosulindac (NCX 1102), a new nitric oxide-donating non-steroidal anti-inflammatory drug, on human bladder carcinoma cell lines
    Huguenin, S
    Vacherot, F
    Kheuang, L
    Fleury-Feith, J
    Jaurand, MC
    Bolla, M
    Riffaud, JP
    Chopin, DK
    MOLECULAR CANCER THERAPEUTICS, 2004, 3 (03) : 291 - 298
  • [10] Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives
    Bolla, M
    Momi, S
    Gresele, P
    Del Soldato, P
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (Suppl 1) : 145 - 154